Abstract Details

Title Folic-targeted Gold Nanoclusters as a Novel Radiosensitizer for Enhancement of The Radiotherapy Efficacy in Glioblastoma-bearing Animals

Topic Neuro-oncology

Presentation(s) P1 - Poster Session 1 (9:00 AM-5:00 PM)

Poster/Presentation
Number 418

Objective The aim of the present study is to investigate folic acid and BSA decorated gold nanoclusters (FA-AuNCs) effect on the enhancement of intracranial C6 glioma tumors radiation therapy (RT) efficacy.

Background Glioblastoma tumors are radioresistance tumors with poor prognosis. Novel nanostructures have gained lots of attention to conquer their radioresistance and enhance the radiotherapy efficacy.

Design/Methods The folic-acid targeted gold nanoclusters (FA-AuNCs) were synthesis and characterized. The targeting efficacy of these nanosytuctures were evaluated in vitro by flow cytometry and fluorescent microscope. The biodistribution, tumor targeting efficacy, and radiosensitizing efficacy of the FA-AuNCs were analyzes Inductively coupled plasma optical emission spectrometry (ICP-OES) in the C6 glioblastoma-bearing Wistar rats.

Results ICP-OES measurements exhibited about 2.5 times more FA-AuNCs uptake by C6 cancer cells (32.8 ng/106 cells) than the normal cells. FA-AuNCs had significantly higher concentration in the brain tumors (8.1 μg/mg) in comparison with surrounding normal brain tissue (4.3 μg/mg). Moreover, FA-AuNCs exhibited dose enhancement factor (DEF) of 1.6. The glioma-bearing rats' survival times were almost doubled at radiation therapy + FA-AuNCs (25.0 ± 1.5 days) in comparison with no-treatment group (12.8 ± 0.7 days). The Ki-67 labeling index was 48.89% ± 9.93 for control, 29.98% ± 8.32 for RT, and 11.53% ± 7.65 for RT + FA-AuNCs. Therefore, FA-AuNCs can be effective radiosensitizers for intracranial glioma tumors RT.

Conclusions The gold nanoclusters exhibited significant radiosensitizing efficacy and considerably enlarged the C6 glioblastoma-bearing animals survival time. So, these nanostructures can be appropriate target for further investigations in higher levels.

Authors/Disclosures
Amirhosein Kefayat, MD PRESENTER	Mr. Kefayat has nothing to disclose.
	No disclosure on file
	No disclosure on file

��ɫ��

��ɫ��